Recro Pharma Announces Presentation of New Meta-Analysis for IV Meloxicam at the 44th Annual Regional Anesthesiology and Acute Pain Medicine Meeting
April 11, 2019 16:05 ET
|
Recro Pharma, Inc.
New Meta-Analysis Data Suggests IV Meloxicam Produces Largest SPID, Greater Reduction in Opioid Use and Better Safety Profile Compared to Other Non-Opioid Medications for Moderate to Severe Pain ...
Recro Pharma Restructures Acute Care Segment While Continuing To Execute on Strong CDMO Segment Performance
April 03, 2019 16:05 ET
|
Recro Pharma, Inc.
Implements Plan to Reduce Acute Care Segment Staff CDMO Segment Continues Strong Performance; Company Increases Revenue, Operating Income and EBITDA, as Adjusted* Guidance for 2019 Expects to Become...
Recro Pharma Appoints Arnaud Ajdler to Its Board of Directors
March 25, 2019 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., March 25, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care...
Recro Pharma Receives Complete Response Letter from the FDA for Intravenous Meloxicam
March 22, 2019 15:30 ET
|
Recro Pharma, Inc.
MALVERN, Pa., March 22, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care...
Recro Pharma to Host Educational Symposium on Pain Management Options in Total Joint Replacements at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting
March 12, 2019 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., March 12, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care...
Recro Pharma Obtains $40.5 Million of Non-Dilutive Capital Through Expanded Credit Facility
March 04, 2019 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., March 04, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care...
Recro Pharma Announces Publication of Phase III IV Meloxicam Clinical Safety and Opioid Use Data in the Journal Clinical Pharmacology in Drug Development
February 25, 2019 16:05 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care...
Recro Pharma Announces New IV Meloxicam Data Publication in the Journal Regional Anesthesia & Pain Medicine
February 20, 2019 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care...
Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018
February 19, 2019 07:00 ET
|
Recro Pharma, Inc.
March 24, 2019 PDUFA Goal Date for IV Meloxicam Record CDMO Performance; 2018 Revenues of $77.3 Million Company to Host Conference Call Today at 8:00 AM ET MALVERN, Pa., Feb. 19, 2019 (GLOBE...
Recro Pharma to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call and Webcast on February 19, 2019
February 14, 2019 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...